Novartis (NVS)
(Delayed Data from NYSE)
$120.89 USD
+0.47 (0.39%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $120.83 -0.06 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Balance Sheet
Fiscal Year End for Novartis AG falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 14,428 | 18,930 | 28,329 | 11,563 | 11,446 |
Receivables | 7,533 | 8,334 | 8,283 | 8,456 | 8,555 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5,913 | 7,175 | 6,666 | 7,131 | 5,982 |
Other Current Assets | 2,607 | 2,471 | 2,440 | 2,523 | 3,521 |
Total Current Assets | 30,481 | 36,910 | 45,718 | 29,673 | 29,504 |
Net Property & Equipment | 9,514 | 10,764 | 11,545 | 12,263 | 12,069 |
Investments & Advances | 2,812 | 2,554 | 3,241 | 9,632 | 11,162 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 4,309 | 3,739 | 3,743 | 8,214 | 7,909 |
Intangibles | 50,220 | 60,945 | 63,777 | 66,808 | 55,311 |
Deposits & Other Assets | 1,199 | 1,110 | 2,210 | 3,793 | 738 |
Total Assets | 99,945 | 117,453 | 131,795 | 132,059 | 118,370 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4,926 | 5,146 | 5,553 | 5,403 | 5,424 |
Current Portion Long-Term Debt | 6,175 | 5,931 | 6,295 | 9,785 | 7,031 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 1,893 | 2,533 | 2,415 | 2,458 | 2,194 |
Other Current Liabilities | 13,166 | 14,795 | 15,670 | 15,127 | 13,369 |
Total Current Liabilities | 26,390 | 28,656 | 30,208 | 33,059 | 28,264 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2,248 | 2,686 | 3,070 | 7,422 | 5,867 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 18,436 | 20,244 | 22,902 | 26,259 | 20,353 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4,523 | 4,906 | 6,172 | 6,934 | 6,632 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 53,195 | 58,030 | 63,973 | 75,393 | 62,819 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 825 | 890 | 901 | 913 | 936 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | 45,883 | 58,544 | 66,802 | 55,738 | 54,618 |
Other Equity | 83 | 81 | 167 | 68 | 77 |
Treasury Stock | 41 | 92 | 48 | 53 | 80 |
Total Shareholder's Equity | 46,750 | 59,423 | 67,822 | 56,666 | 55,551 |
Total Liabilities & Shareholder's Equity | 99,945 | 117,453 | 131,795 | 132,059 | 118,370 |
Total Common Equity | 46,750 | 59,423 | 67,822 | 56,666 | 55,551 |
Shares Outstanding | 2,044.00 | 2,119.60 | 2,236.70 | 2,288.70 | 2,265.00 |
Book Value Per Share | 22.87 | 28.04 | 30.32 | 24.76 | 24.53 |
Fiscal Year End for Novartis AG falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 8,435 | 9,694 | 14,428 | 12,695 | 11,174 |
Receivables | 8,480 | 8,251 | 7,533 | 7,099 | 9,543 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5,747 | 5,743 | 5,913 | 5,610 | 8,228 |
Other Current Assets | 3,031 | 2,759 | 2,607 | 20,256 | 4,548 |
Total Current Assets | 25,693 | 26,447 | 30,481 | 45,660 | 33,493 |
Net Property & Equipment | 9,254 | 9,200 | 9,514 | 9,044 | 10,825 |
Investments & Advances | 2,126 | 2,582 | 2,812 | 2,122 | 2,433 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 4,400 | 4,219 | 4,309 | 3,628 | 4,043 |
Intangibles | 53,009 | 49,335 | 50,220 | 49,834 | 57,525 |
Deposits & Other Assets | 1,655 | 1,209 | 1,199 | 1,109 | 1,208 |
Total Assets | 97,505 | 94,334 | 99,945 | 112,697 | 110,979 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4,146 | 4,062 | 4,926 | 3,870 | 5,350 |
Current Portion Long-Term Debt | 7,532 | 8,339 | 6,175 | 5,458 | 8,289 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 1,919 | 1,650 | 1,893 | 2,129 | 2,651 |
Other Current Liabilities | 13,783 | 15,012 | 13,166 | 36,726 | 15,372 |
Total Current Liabilities | 27,612 | 29,288 | 26,390 | 48,393 | 31,909 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2,456 | 2,311 | 2,248 | 2,457 | 2,526 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 19,663 | 17,191 | 18,436 | 18,068 | 18,259 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4,312 | 4,523 | 4,081 | 4,809 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 55,603 | 54,578 | 53,195 | 74,452 | 59,048 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 793 | 793 | 825 | 825 | 842 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | 40,965 | 38,899 | 45,883 | 37,371 | 51,057 |
Other Equity | 169 | 81 | 83 | 81 | 84 |
Treasury Stock | 25 | 17 | 41 | 32 | 52 |
Total Shareholder's Equity | 41,902 | 39,756 | 46,750 | 38,245 | 51,931 |
Total Liabilities & Shareholder's Equity | 97,505 | 94,334 | 99,945 | 112,697 | 110,979 |
Total Common Equity | 41,902 | 39,756 | 46,750 | 38,245 | 51,931 |
Shares Outstanding | 2,044.00 | 2,044.00 | 2,044.00 | 2,119.60 | 2,119.60 |
Book Value Per Share | 20.50 | 19.45 | 22.87 | 18.04 | 24.50 |